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Abstract
Background: Patients with DLBCL who are ineligible for or have relapsed after aggressive salvage chemotherapy
have a poor prognosis. CD40 is expressed on multiple B-cell neoplasms including DLBCL and is a potential target
for immunotherapy. Dacetuzumab (SGN-40), a non-blocking, partial agonist, humanized IgG1, anti-CD40 monoclonal
antibody, has previously demonstrated anti-lymphoma activity in a phase I study.
Methods: A phase II study was undertaken to evaluate the rate and duration of objective responses and safety of
single-agent dacetuzumab in relapsed DLBCL. Forty-six adult patients with relapsed/refractory DLBCL received up to
12 cycles of intravenous dacetuzumab using intrapatient dose-escalation to a target dose of 8 mg/kg/week in an
initial 5-week cycle, followed by 4-week cycles of 8 mg/kg/week. Study endpoints included rate and duration of
objective responses, safety, survival, pharmacokinetics, immunogenicity, and exploratory correlative studies.
Results: Overall response rate was 9% and disease control rate (complete remission + partial remission + stable
disease) was 37%. Common non-hematologic adverse events (AEs) included fatigue, headache, chills, fever, and
nausea. The most frequent Grade 3–4 non-hematologic AE was deep venous thrombosis (3 patients). Grade 3–4
lymphopenia (41%), neutropenia (13%), or thrombocytopenia (19%) occurred without associated infection or bleeding.
Reversible ocular events, including conjunctivitis and ocular hyperemia, occurred in 8 patients (17%). Patient-specific
factors, including Fc-gamma-RIIIa polymorphism, did not appear to correlate with antitumor activity.
Conclusions: Single-agent dacetuzumab has modest activity and manageable toxicity in unselected patients with
relapsed DLBCL. Combination regimens and robust methods of patient selection may be necessary for further
development.
Trial registration: ClinicalTrials.gov identifier NCT00435916.
Keywords: Diffuse large B-cell lymphoma, DLBCL, Dacetuzumab, CD40
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Background
Although the outcome of patients with diffuse large
B-cell lymphoma (DLBCL) has improved considerably in
the rituximab era [1-3], patients who experience relapse
after initial rituximab-containing chemotherapy or after
a salvage regimen have a poor prognosis. A significant
number of patients are ineligible for aggressive salvage
therapy or autologous stem cell transplantation (ASCT)
due to comorbid conditions or advanced age. The CORAL
study [4] established that patients with DLBCL who
relapsed within a year after first-line therapy with R-CHOP
have a poor response and survival after ASCT when
compared to historical data in patients who relapse after
CHOP alone. Thus, better therapeutic options are
urgently needed for this population.
CD40 is a member of the TNF-receptor superfamily
that functions as a co-stimulatory molecule upon interaction with its ligand CD154 (CD40L) [5]. CD40 is
expressed on several types of B-cell neoplasms, including
non-Hodgkin lymphoma (NHL), multiple myeloma, and
chronic lymphocytic leukemia, making it an attractive
potential tumor target for antibody-based cancer therapy
[6]. Dacetuzumab (also known as SGN-40) is a humanized IgG1 form of S2C6, a murine anti-human CD40
monoclonal antibody (mAb). In contrast to blocking
anti-CD40 mAbs, dacetuzumab does not prevent CD40/
CD40L interactions, and the antibody behaves as a
partial agonist in vitro. Dacetuzumab has little effect on
normal cells in vitro, but in the presence of cross-linking
reagents and certain cytokines or growth factors (e.g.,
interleukin-4 [IL-4]), it enhances the proliferation of
responsive cells, such as normal B-cells [7]. In vitro and
in vivo studies with the CD40-positive lymphoma lines
Ramos and IM-9 demonstrated that dacetuzumab
induces apoptosis and inhibits growth of CD40-positive
lymphoma lines through direct signal transduction and
kills tumor cells through antibody-dependent cellular
cytotoxicity (ADCC) and phagocytosis (ADCP). The
relevance of both direct and cell-mediated mechanisms
was apparent in in vivo models [7]. It has been demonstrated that agonistic CD40 antibodies may mediate
antitumor activity through activation of CD40-positive
antigen presenting cells, including dendritic cells [8,9].
A phase I study of dacetuzumab was conducted in 50
patients with refractory or recurrent B-cell NHL, including DLBCL, mantle cell lymphoma, follicular lymphoma,
small lymphocytic lymphoma, and marginal zone lymphoma [10]. Toxicity appeared acceptable and antitumor
activity was observed with 6 objective responses (12%),
and 13 patients with stable disease (26%). The overall
response rate (ORR) for patients with refractory or
recurrent DLBCL was 18% (4 of 21 patients) and provided the rationale for further evaluation of dacetuzumab in this patient population.
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The primary objectives of the current study were to
determine the ORR, response duration, and safety profile of dacetuzumab in patients with relapsed DLBCL.
Secondary objectives included evaluation of survival,
pharmacokinetics, immunogenicity, and exploratory analyses to determine whether the antitumor activity of
dacetuzumab was associated with FcγR polymorphisms
or DLBCL molecular subtypes.

Methods
Patients

Adults with a histologically confirmed diagnosis of DLBCL,
measurable disease, and an ECOG performance status
of ≤2 were eligible. Inclusion criteria included at least 1
prior systemic therapy consisting of combination chemotherapy and rituximab; progression since the most recent
therapy; and received standard salvage therapy including
ASCT unless deemed ineligible due to age or comorbidities. At the time of enrollment, patients must have been at
least 12 weeks from ASCT, 4 weeks from chemotherapy
or monoclonal antibody treatment, and 2 weeks from
radiation or treatment with immunomodulatory agents.
Exclusion criteria included previous diagnosis or treatment for indolent lymphoma; primary refractory disease;
progression while receiving salvage therapy; leptomeningeal or central nervous system lymphoma; prior allogeneic
transplant; or prior treatment with any anti-CD40 antibody. This was a multicenter study conducted at 10 sites
in the United States. Each institution’s Ethics Committee
approved the protocol and patients provided written
informed consent.
Study design

For Cycle 1, all patients were treated using an intrapatient dose-escalation schedule to reduce the risk of
first-dose toxicities (Table 1) [10]. Subsequent cycles
consisted of 4 doses of 8 mg/kg on Days 1, 8, 15, and
22. Patients were medicated before and after dacetuzumab
infusion with acetaminophen and diphenhydramine.
Steroids were allowed for the prevention and treatment
of cytokine release syndrome. Patients were treated with
2 cycles after a complete remission (CR) or until disease
progression for a maximum of 12 cycles.
Clinical response was assessed by PET-CT scanning
after Cycles 1 and 2 and then after even cycles through
Cycle 6; CT scans (without PET) were done after Cycles 8,
10, and 12. Responses were scored as CR, partial remission
(PR), stable disease (SD), or progressive disease (PD), as
defined by the 1999 criteria from the International
Workshop on Malignant Lymphoma [11]. Severity of
adverse events (AEs) and clinical laboratory values were
graded using the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0.
Serum concentrations of SGN-40 were measured using
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Table 1 Schedule and doses of dacetuzumab in Cycle 1 and additional cycles
Dacetuzumab dose, mg/kg
Week 1

Week 1

Week 2

Week 3

Week 4

Week 5

Week 6

Day 1

Day 4

Day 8

Day 15

Day 22

Day 29

Day 36

Cycle 1

1

2

4

8

8

8

Restage

Cycles 2-12

8

—

8

8

8

Restage

—

a validated bridging enzyme-linked immunosorbent
assay (ELISA) with a lower limit of quantitation of
0.040 μg/mL. The presence of anti-dacetuzumab (antihuman) antibodies was assessed by Tandem Laboratories (West Trenton, NJ) using a validated enzyme linked
immunosorbent assay. Concentrations of circulating
cytokines (TNF-alpha, IL-1 beta, IL-6, IL-10, IFN-gamma)
were measured by immunofluorescence bead technique
at Millipore Corporation (St. Charles, MO). Circulating
lymphocyte subsets (CD19+, CD3+, CD3 + CD4+, CD3 +
CD8+), monocytes (CD14+), and NK cells (CD16+
CD56+) were measured by flow cytometry at Roswell
Park Cancer Institute (Buffalo, NY).
Correlative studies

A retrospective central pathologic review was conducted
by a core lab (Phenopath Laboratories, Seattle, WA).
Cases with discordant pathology were adjudicated by
R. Gascoyne, MD, University of British Columbia,
Vancouver, Canada. Immunohistochemistry was performed for pathologic disease confirmation, DLBCL
subtype determination, and CD40 expression. The
Hans classification method [12] was used to classify
DLBCL subtypes. Immunohistochemistry stains included
antibodies against CD20, CD10, Bcl-6, MUM1, Ki67, and
CD40. Fcγ receptor IIa and IIIa polymorphism analyses
were conducted by W. Weng, MD, Stanford University,
Stanford, CA, using the TaqMan technology on an ABI
Prism 7900HT Sequence Detector System (Applied
Biosystems) as previously described [13].
Statistics

Analyses of data from this study were primarily descriptive. Missing data were not imputed. Safety and efficacy
evaluations were performed on all patients who received any study drug (i.e., safety/modified intent-totreat [mITT] set). It was expected that approximately
40 patients would be enrolled in the study to ensure at
least 35 study-compliant patients who received at least
1 infusion of 8 mg/kg. With 35 patients, assuming an
alpha error of 0.05 and a targeted observed response
rate of 25%, a one-sided 95% confidence interval would
exclude a response rate ≤12%. The Kaplan-Meier method
was used to estimate time-to-event endpoints. Maximum
observed concentration (Cmax) and minimum observed
concentration (Ctrough) were derived from the observed

serum concentration data and analyzed descriptively. The
effects of FcγR polymorphisms and DLBCL molecular
subtype on objective response rate were examined using
Fisher’s exact test. Data management and statistical
analysis were performed by Seattle Genetics, Inc. All
co-authors had access to the primary study data.

Results
Patients

A total of 46 patients were enrolled between December
2006 and January 2009. Patients’ characteristics at study
entry are summarized in Table 2. The median number of
prior therapies was 3 (range: 1–9) and 35% of subjects
had previously undergone ASCT.
Enrollment was based on a diagnosis of de novo
DLBCL at the treating institution, but a pre-planned
central pathologic evaluation suggested a discordant
diagnosis in 11 patients (24%). Post-hoc adjudication by
a third-party pathologist confirmed DLBCL in 40 patients, with other diagnoses in 6 patients (13%) [follicular Grade 2 (3 patients); marginal zone (2 patients); large
cell lymphoma of undetermined lineage (1 patient)].
A total of 85 complete or partial cycles of dacetuzumab
were administered. Thirty-one patients received one cycle,
7 received 2, 5 received 4, 2 received 6, and one received
8 cycles. The most frequent reasons for discontinuing therapy were progressive disease (n = 32, 70%), followed by
adverse events (n = 8, 17%), investigator decision (n = 2,
4%), withdrawn consent (n = 1, 2%), and “other” (n = 3,
7%). Eight patients had a total of 14 dacetuzumab doses
delayed for one week due to adverse events; 6 of these
delays were in a single patient who had a CR and received
a total of 8 treatment cycles. Persistent thrombocytopenia,
which had been present (approximately 100,000/mm3) at
study entry and likely indicative of heavy prior therapy
including prior autologous bone marrow transplant, was
implicated in 5 of 6 of those dose delays. This patient also
skipped a dose due to an adverse event (diarrheal illness).
Five patients each had one dose interrupted but subsequently completed due to an infusion reaction (4 patients)
or other adverse event (1 patient). Per protocol, there were
no reductions in any dacetuzumab dose.
Safety

Of the 46 patients, 45 (98%) experienced at least one AE
during the study and 21 patients (46%) had at least one
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Characteristic

Median [range]
or No. (%)

Table 3 (A) Treatment-emergent non-hematologic
adverse events occurring in greater than 10% of patients
and (B) Grade 3–4 hematologic abnormalities (N = 46)

Age, years

72 [17–85]

(A)

Male gender

28 (61)

ECOG status

Severity grade, n (%)
Preferred term

1

2

3

4

Overall (N = 46)

9 (20)

8 (17)

2 (4)

0

19 (41)

0

16 (35)

Fatigue

1

23 (50)

Headache

14 (30)

2 (4)

0

0

16 (35)

2

6 (13)

Chills

11 (24)

3 (7)

1 (2)

0

15 (33)

Unknown

1 (2)

Pyrexia

8 (17)

4 (9)

0

0

12 (26)

Time since diagnosis, years

2.9 [0–21]

Nausea

8 (17)

2 (4)

1 (2)

0

11 (24)

Number of prior systemic therapies

3 [1-9]

Diarrhoea

8 (17)

1 (2)

0

0

9 (20)

16 (35)

Dyspnoea

4 (9)

5 (11)

0

0

9 (20)

Cough

7 (15)

0

0

0

7 (15)

3 (7)

2 (4)

1 (2)

0

6 (13)

Prior ASCT
Diagnosis after confirmatory review
DLBCL

40 (87)

Back pain

Follicular NHL (grade 2)

3 (7)

Depression

4 (9)

2 (4)

0

0

6 (13)

Marginal zone

2 (4)

Musculoskeletal pain

4 (9)

2 (4)

0

0

6 (13)

Diffuse large cell NHL, lineage undetermined

1 (2)

Abdominal pain

1 (2)

2 (4)

2 (4)

0

5 (11)

Asthenia

2 (4)

2 (4)

1 (2)

0

5 (11)

14 (30)

Constipation

5 (11)

0

0

0

5 (11)

Non-GCB

14 (30)

Oedema peripheral

4 (9)

1 (2)

0

0

5 (11)

Missing

18 (39)

Oropharyngeal pain

5 (11)

0

0

0

5 (11)

Vomiting

2 (4)

2 (4)

1 (2)

0

5 (11)

DLBCL subtype
GCB

CD40 staining intensity
0

1 (2)

1+

2 (4)

2+

13 (28)

3+

25 (54)

Not available

5 (11)

ECOG, Eastern Cooperative Oncology Group; ASCT, autologous stem cell
transplantation; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center
B-cell; NHL, non-Hodgkin lymphoma.

AE of Grade 3 or higher. Forty-one patients (89%) had
at least one AE considered by the treating investigator to
be related to dacetuzumab. The most common nonhematologic AEs observed (Table 3A), irrespective of
their relationship to dacetuzumab, were Grade 1 or 2
and consisted of fatigue (19 patients [41%]), headache
(16 patients [35%]), chills (15 patients [33%]), pyrexia
(12 patients [26%]), nausea (11 patients [24%]), diarrhea
(9 patients [20%]), and dyspnea (9 patients [20%]). Grade
3–4 hematologic abnormalities were observed in 13
patients (41%; Table 3B).
Eighteen patients (39%) had at least one serious
adverse event (SAE) and 8 patients experienced 16 SAEs
evaluated as possibly related to dacetuzumab by the
treating investigators. These possibly related SAEs included
acute pancreatitis and hyperglycemia (2 episodes of each),
pneumonia, pancytopenia, fatigue, confusional state, acute
renal failure, nausea, dehydration, vomiting, abdominal

(B)
Grade 3

Grade 4

n (%)

n (%)

Lymphopenia

14 (30)

5 (11)

Neutropenia

5 (11)

1 (2)

Thrombocytopenia

7 (15)

2 (4)

Leukopenia

6 (13)

1 (2)

pain, small intestinal obstruction, febrile neutropenia, and
orbital cellulitis (one episode each).
Previous studies have also reported inflammatory eye
disorders, elevation of hepatic transaminases, and symptoms of cytokine release syndrome (CRS) with dacetuzumab [10,14]. These events were observed in our study
as well, generally within 2 weeks of starting study drug
and were for the most part Grade 1 or 2 (Table 4). Eye
disorders, including conjunctivitis and ocular hyperemia,
experienced by 8 patients (17%) were considered possibly
related to dacetuzumab in 6 of these patients. All reports
of eye disorders resolved, most within 3 weeks. All were
Grade 1 or 2 in severity with the exception of one report
of unrelated Grade 3 conjunctival hemorrhage. Additionally, one of these 8 patients had severe orbital cellulitis
related to an infection that resulted in enucleation. This
patient had a preceding history of ocular H. zoster and
developed a streptococcal orbital cellulitis/endophthalmitis, in the setting of a normal neutrophil count and
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Table 4 Ocular toxicities
Patient ID

AE (Preferred term)

Study day of onset

Duration (Days)

Severity

Relation to SGN-40

029-0010

Eye pain

1

4

Grade 1

Possibly

Eye pain

5

3

Grade 1

Possibly

Eye pain

8

4

Grade 1

Possibly

029-0011

044-0001

Eye irritation

1

1

Grade 1

Possibly

Vision blurred

8

1

Grade 1

Possibly

Conjunctivitis

5

14

Grade 2

Probably

Eye pain

11

11

Grade 2

Possibly

Eye infection

16

4

Grade 2

Unlikely

Orbital cellulitis (SAE)

18

4

Grade 3

Possibly

059-0001

Dry eye

16

8

Grade 2

Possibly

066-0010

Conjunctival irritation

16

22

Grade 1

Possibly

Eye pain

37

36

Grade 1

Possibly

066-0011

Conjunctival hyperaemia

4

11

Grade 2

Possibly

066-0005

Conjunctival hyperaemia

1

56

Grade 1

Unrelated

005-0002

Conjunctival hemorrhage

17

1

Grade 3

Unrelated

pre-existing B lymphopenia. The treating investigator
reported the overall event as possibly related to dacetuzumab. Asymptomatic elevations of hepatic transaminases
(AST or ALT) were reported in 18 patients as Grade 1–2
and in one patient as Grade 3. Symptoms potentially reflective of cytokine release syndrome (CRS) were observed
in 35 patients (76%) and occurred after the first dose of
dacetuzumab in 21 patients (46%). Of these, only one
patient had Grade 3 CRS symptoms. A four-fold elevation
in serum levels of one or more cytokines was observed on
treatment Day 1 in 13 patients and in conjunction with
symptoms possibly associated with CRS for 8 of these
patients. The only death during treatment was unrelated
to dacetuzumab (self-inflicted gunshot wound).
Consistent with prior rituximab treatment, all patients
entered the study with low numbers of CD19+ cells in
peripheral blood (<450 cells/μL), and more than half
(57%) had initial CD19+ counts <10 cells/μL. An evaluation of the 9 patients with >100 CD19+ cells/μL at
baseline and with post-treatment data available revealed
rapid and persistent decreases in B-cells after infusion of
dacetuzumab. No other consistent changes in mononuclear cell subsets were noted (data not shown).
Among 32 patients with both pre- and post-treatment
data available, no anti-dacetuzumab antibodies were
detected. Low titer immune responses could have been
missed due to assay interference from dacetuzumab in
the sample. Accumulation of dacetuzumab in serum was
observed with repeated administration throughout Cycle
1 and subsequent cycles. Peak and trough concentrations
increased to means of 204 ± 43.2 and 101 ± 37 μg/mL,
respectively, by the end of Cycle 1. Peak concentrations
continued to increase at the end of each cycle to 329 ±

84.7 μg/mL for the 3 patients completing the end of
Cycle 6, and 465 μg/mL for the one patient completing
the end of Cycle 8. The concentration vs. nominal
collection time profile was consistent with a biphasic
pharmacokinetic pattern (data not shown). Limited
sampling precluded calculation of parameters such as
clearance and elimination half-life.
Efficacy

On an intent-to-treat basis, objective responses (CR and
PR) were observed in 4 of 46 patients (9%; 2 CR, 2 PR)
and 13 patients had SD (28%; Table 5), resulting in a
disease control rate of 37% (Figure 1A). The response
scores for these patients were consistent between the
1999 and 2007 (revised) response criteria [11,15]. On
independent pathology review, 3 of the responders were
confirmed to have DLBCL while one partial responder
had a diffuse variant of Grade 2 follicular lymphoma.
One of the complete responders, with primary cutaneous DLBCL leg type, had multiple right lower extremity
skin lesions on physical exam and on PET imaging. This
patient had previously failed R-CHOP/radiation therapy,
and experienced relapse 4 months after salvage therapy
with R-ICE/radioimmunotherapy. After treatment with
dacetuzumab, the patient’s lesions completely resolved
both clinically and radiologically (Figure 1B). The objective response duration was over one year, after which
recurrent DLBCL was documented by biopsy. A second
course of dacetuzumab (6 cycles) was then administered
under a compassionate use protocol, resulting in a near
CR; this second response was ongoing after more than
20 months. The other complete responder, who had
received 4 prior chemotherapy regimens including ASCT
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Table 5 Investigator assessment of best clinical responsea
Best clinical
response
CRb

All patients
(N = 46), n (%)
2 (4)

PR

2 (4)

SD

13 (28)

PD

26 (57)

Unknownc
a

Per response criteria in Cheson et al. [11].
Both CRs were confirmed.
No post-baseline evaluations available.

b
c

3 (7)

plus radiotherapy, had complete radiographic resolution
of multiple nodes of which the largest was 7.7 × 3.6 cm
at baseline. This patient had an objective response
duration of 262 days. The 2 PRs lasted 78 and 78+ days;
the latter case was that of a patient with Grade 2 follicular lymphoma who had enrolled on study due to
inability to tolerate intensive salvage therapy, and after
achieving a PR with 4 cycles of dacetuzumab, proceeded
to ASCT. Duration of SD exceeded 120 days in 3
patients. Overall, the median progression-free survival
was 36 days (range, 1-438+ days, Figure 2).
Exploratory correlative evaluations

There was no significant correlation between responses or
disease control and FcγR IIa and FcγR IIIa polymorphisms,

Figure 1 (A) Maximum reduction in target lesions and (B) complete remission in 80-year-old female with multiple subcutaneous and
skin lesions of multifocal primary cutaneous DLBCL leg type. Waterfall plot of maximum reduction in target lesions for all patients with data
before and after treatment with dacetuzumab. Each bar represents change in the sum of the product of perpendicular diameters (SPD) for an
individual patient (*denotes pictured case study).
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Overall, the safety profile for dacetuzumab was acceptable and manageable in this patient population. Consistent with prior experience and the known cellular target
of dacetuzumab, there was evidence of dacetuzumabrelated B-cell depletion. Baseline lymphopenia likely
reflects, in large part, extensive prior treatment of the
study patients with multiple myelosuppressive regimens and rituximab. Total lymphocyte depletion >
Grade 3 was identified in 18% of patients, but did not
result in high rates of clinical infections. A notable exception was a single case of bacterial orbital cellulitis requiring enucleation after ocular inflammation. Noninfectious
ocular inflammation has been potentially attributed to
reports of CD40 expression on conjunctival tissue, and
mild conjunctival symptoms reported 12-21% of patients
in phase I trials with dacetuzumab [10,14,16]. Consistent
with prior phase I experience, mild symptoms related to
CRS were noted, easily managed with premedications
and did not compromise the ability to administer dacetuzumab. The rate of elevated asymptomatic hepatic
transaminase values was also consistent with prior
clinical experience. The observed dacetuzumab serum

Figure 2 Kaplan-Meier plot of progression-free survival (PFS)
for modified intent-to-treat (mITT) population (solid line).
Dashed lines represent 95% confidence intervals and circles indicate
censored patients.

DLBCL molecular subtype, CD40 expression level, or prior
ASCT (Table 6).

Discussion
This study confirms and extends prior clinical observations of the anti-CD40 antibody dacetuzumab administered to patients with non-Hodgkin lymphoma [10].
Table 6 Subgroup analyses
Available data

Number of responders

n (%)

(CR + PR)

FcγRIIa polymorphism (N = 27)

Number with disease control

13 (48)

0

4

H/H

7 (26)

1

2

R/R

7 (26)

2

5
>0.99

0.72

V/F

13 (41)

2

6

F/F

12 (38)

1

4

V/V

7 (22)

1

2
0.66

>0.99

GCB

14 (52)

1

4

ABC

11 (41)

2

4

2 (7)

0

Other
CD40 staining intensity (N = 38)

1
0.17

0.24

3+

22 (58)

3

8

2+

13 (34)

0

7

1+

2 (5)

1

2

0

1 (3)

0

0

≥2+ and ≥80% positive

33 (87)

3

<2+ OR <80% positive

5 (13)

1

CD40 expression (N = 38)

0.45

Prior ASCT (N = 43)

>0.99
15
2

0.62

0.75

Yes

16 (37)

2

7

No

27 (63)

2

10

Fisher’s exact test.

a

0.19

H/R

DLBCL molecular subtype (N = 27)

p-value

(CR + PR + SD)
0.12

FcγRIIIa polymorphism (N = 32)

a

p-valuea
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concentrations and the absence of host antibody
responses also mirrored prior clinical experience.
In this study, restricted to a heavily pretreated DLBCL
population, a 9% objective response rate was observed
with a disease control rate of 37% (CR + PR + SD). In a
retrospective pathology review, 1 patient with a PR was
found to have Grade 2 follicular lymphoma. Therefore,
the ORR for confirmed DLBCL patients in this study
was 7%. This trial confirms the limited single-agent
antitumor activity of dacetuzumab in aggressive NHL
reported in the phase I trial [10]. Though infrequent, the
individual responses seen in the present trial were
robust. Most notable was a durable CR that was attained
in a case of multifocal primary cutaneous DLBCL leg
type, a distinct DLBCL subtype with characteristic
molecular features and an unfavorable prognosis [17,18],
that had relapsed shortly after failure of aggressive
salvage therapy. Moreover, at a subsequent relapse, the
patient’s disease again responded nearly completely to
re-treatment with dacetuzumab. A second CR was obtained in a patient who had previously failed therapy
with multiple regimens, including ASCT. The individual
responses observed suggest that selected patients with
DLBCL could benefit from treatment with dacetuzumab.
DLBCL is a notably heterogeneous group of lymphomas with different pathogeneses, driver mutations,
and pathway dependencies. CD40-targeting is a precise
therapeutic approach. It is not surprising that only a
subset of unselected patients with DLBCL benefited
from treatment with dacetuzumab. Predictive biomarkers
may allow enriching the patient population likely to
respond. However, predetermined correlative studies
in the present trial did not identify factors that could
predict clinical benefit. Specifically, the uniformity and
intensity of CD40 expression, DLBCL subtype, and
FcγR polymorphism did not correlate with response or
stable disease.
In contrast, Burington et al. [19] examined the activation status of the CD40 pathway, and identified and
validated an associated 15-gene qRT-PCR signature
generated from preclinical models of NHL. The 15-gene
signature predicted outcomes following CD40 pathway
stimulation and suggested that CD40 activation status
was a significant factor predicting response. It was
applied to patient samples from two separate dacetuzumab monotherapy studies. Data from 28 of the 39
patient samples used in the training set for the clinical
exploratory work were collected as part of the present
phase II trial. A low baseline CD40 pathway activity
correlated with high sensitivity to dacetuzumab and a
high baseline CD40 pathway activity correlated with
resistance to dacetuzumab [19]. The mechanism of
resistance to dacetuzumab might be the selective activation of the noncanonical NF-κB signaling pathway in

Page 8 of 9

constitutively active CD40 receptors that could promote cell survival by shifting the balance to an antiapoptotic response [20]. A limitation of this signature
is that it only relates to the CD40 signaling mechanism
of action of SGN-40 and does not take into account
other potential mechanisms, such as effector functions
(e.g., ADCC) or activation of immune cells (APCs).
Therefore, additional work is needed to identify which
patient-specific characteristics may be associated with
response to dacetuzumab.
Preclinical studies with dacetuzumab have shown
synergy when combined with rituximab or combination
chemotherapy in animal models [21,22]. This has led to
additional trials of dacetuzumab in combination with
standard agents. Activity in relapsed DLBCL was reported
in a single-arm Phase Ib trial of dacetuzumab in combination with rituximab and gemcitabine, showing an
ORR of 47% (14 of 30 patients) in relapsed or refractory
DLBCL [23]. Separately, a randomized phase IIb trial
of rituximab, ifosfamide, carboplatin, and etoposide (R-ICE)
with or without dacetuzumab was conducted in patients
who previously failed R-CHOP. Although the trial was
stopped early due to failure to increase the CR rate,
extended follow-up demonstrated a trend toward increased survival for those patients who were randomized to receive dacetuzumab [24]. These studies
suggest that dacetuzumab may be beneficial when
combined with active regimens. However, the selection
criteria to identify these patients have not been identified. Any future development of dacetuzumab should
evaluate the multiple potential mechanisms of action
that have been documented preclinically, including
ADCC, ADCP, induction of apoptosis by signaling
through CD40 on malignant cells, and immunomodulation by activation of CD40-expressing immune cells.

Conclusions
In summary, this phase II trial of single-agent dacetuzumab confirms that the partial-agonist anti-CD40 is well
tolerated and has modest activity in heavily pretreated
patients with DLBCL. Because DLBCL is a heterogeneous disease, the challenges ahead are to identify the
subset of patients in whom response could be predicted
and to develop rationally designed clinical trials.
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